Application of the Lancet Commission COPD classification to COPD Cohort Population in South Korea

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Respiratory medicine Pub Date : 2024-05-24 DOI:10.1016/j.rmed.2024.107679
Hyonsoo Joo , Hyoung Kyu Yoon , Yong Il Hwang , Sang Hyuk Kim , Soo-Jung Um , Won-Yeon Lee , Ki-Suck Jung , Kwang Ha Yoo , Woo Jin Kim , Chin Kook Rhee
{"title":"Application of the Lancet Commission COPD classification to COPD Cohort Population in South Korea","authors":"Hyonsoo Joo ,&nbsp;Hyoung Kyu Yoon ,&nbsp;Yong Il Hwang ,&nbsp;Sang Hyuk Kim ,&nbsp;Soo-Jung Um ,&nbsp;Won-Yeon Lee ,&nbsp;Ki-Suck Jung ,&nbsp;Kwang Ha Yoo ,&nbsp;Woo Jin Kim ,&nbsp;Chin Kook Rhee","doi":"10.1016/j.rmed.2024.107679","DOIUrl":null,"url":null,"abstract":"<div><p>The Lancet Commissions on COPD recommended a new classification based on five main risk factors.</p><p>Patients with COPD were prospectively enrolled in a Korean COPD subgroup study cohort between April 2012 and June 2022. Patients were classified according to the etiologies (Type 1: Genetically determined (COPD-G), Type 2: Abnormal lung development (COPD-D), Type 3: Infections (COPD-I), Type 4: Cigarette smoking (COPD-C), Type 5: Biomass and pollution (COPD-P)).</p><p>The database enrolled 3476 patients. Among 3392 patients, 52 (2 %), 1339 (39 %), 2930 (86 %), and 2221 (65 %) were compatible with type 2 (COPD-D), 3 (COPD-I), 4 (COPD-C), and 5 (COPD-P), respectively. Most patients (71 %, 2405) had multiple risk factors contributing to their COPD. However, 93, 712, and 182 patients had only type 3 (COPD-I), 4 (COPD-C), and 5 (COPD-P), respectively. Type 3 (COPD-I) only patients were significantly younger, more often female, and had lower lung function. Both the rate and frequency of severe exacerbations were significantly higher in type 3 (COPD-I) only patients (p = 0.038 and p = 0.048, respectively). Compared with type 5 (COPD-P) only, type 3 (COPD-I) only was significantly associated with the risk of severe exacerbation (Odds ratio, 5.7 [95 % CI, 1.0–32.4]; P = 0.049, incident rate ratio, 8.7 [95 % CI, 1.7–44.0]; P = 0.009).</p><p>Many patients were affected by multiple factors. Therefore, it is important to consider not only smoking history, but also other potential risk factors when evaluating patients with COPD. Further research is needed to explore the implications of this new COPD classification system for clinical practice and treatment strategies.</p></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0954611124001537/pdfft?md5=13bd89eb64b3379c34e17bf8dae204b6&pid=1-s2.0-S0954611124001537-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124001537","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The Lancet Commissions on COPD recommended a new classification based on five main risk factors.

Patients with COPD were prospectively enrolled in a Korean COPD subgroup study cohort between April 2012 and June 2022. Patients were classified according to the etiologies (Type 1: Genetically determined (COPD-G), Type 2: Abnormal lung development (COPD-D), Type 3: Infections (COPD-I), Type 4: Cigarette smoking (COPD-C), Type 5: Biomass and pollution (COPD-P)).

The database enrolled 3476 patients. Among 3392 patients, 52 (2 %), 1339 (39 %), 2930 (86 %), and 2221 (65 %) were compatible with type 2 (COPD-D), 3 (COPD-I), 4 (COPD-C), and 5 (COPD-P), respectively. Most patients (71 %, 2405) had multiple risk factors contributing to their COPD. However, 93, 712, and 182 patients had only type 3 (COPD-I), 4 (COPD-C), and 5 (COPD-P), respectively. Type 3 (COPD-I) only patients were significantly younger, more often female, and had lower lung function. Both the rate and frequency of severe exacerbations were significantly higher in type 3 (COPD-I) only patients (p = 0.038 and p = 0.048, respectively). Compared with type 5 (COPD-P) only, type 3 (COPD-I) only was significantly associated with the risk of severe exacerbation (Odds ratio, 5.7 [95 % CI, 1.0–32.4]; P = 0.049, incident rate ratio, 8.7 [95 % CI, 1.7–44.0]; P = 0.009).

Many patients were affected by multiple factors. Therefore, it is important to consider not only smoking history, but also other potential risk factors when evaluating patients with COPD. Further research is needed to explore the implications of this new COPD classification system for clinical practice and treatment strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
柳叶刀委员会慢性阻塞性肺病分类在韩国慢性阻塞性肺病队列人群中的应用
柳叶刀慢性阻塞性肺病委员会建议根据五个主要风险因素进行新的分类。2012 年 4 月至 2022 年 6 月期间,韩国慢性阻塞性肺病亚组研究队列对慢性阻塞性肺病患者进行了前瞻性登记。根据病因对患者进行了分类(类型1:遗传决定(COPD-G);类型2:肺发育异常(COPD-D);类型3:感染(COPD-I);类型4:吸烟(COPD-C);类型5:生物质和污染(COPD-P))。在 3392 名患者中,分别有 52 人(2%)、1339 人(39%)、2930 人(86%)和 2221 人(65%)符合 2 型(慢性阻塞性肺病-D)、3 型(慢性阻塞性肺病-I)、4 型(慢性阻塞性肺病-C)和 5 型(慢性阻塞性肺病-P)。大多数患者(2405 人,占 71%)有多种导致慢性阻塞性肺病的危险因素。然而,分别有 93、712 和 182 名患者只有 3 型(慢性阻塞性肺病-I)、4 型(慢性阻塞性肺病-C)和 5 型(慢性阻塞性肺病-P)。只有 3 型(COPD-I)的患者明显更年轻、更多为女性、肺功能更低。仅 3 型(COPD-I)患者的严重恶化率和频率都明显更高(分别为 p = 0.038 和 p = 0.048)。与仅患 5 型(慢性阻塞性肺病-P)的患者相比,仅患 3 型(慢性阻塞性肺病-I)的患者发生严重恶化的风险明显更高(Odds ratio,5.7 [95 % CI,1.0-32.4];P = 0.049,事故率比,8.7 [95 % CI,1.7-44.0];P = 0.009)。因此,在评估慢性阻塞性肺病患者时,不仅要考虑吸烟史,还要考虑其他潜在的风险因素。还需要进一步研究探讨这一新的慢性阻塞性肺病分类系统对临床实践和治疗策略的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory medicine
Respiratory medicine 医学-呼吸系统
CiteScore
7.50
自引率
0.00%
发文量
199
审稿时长
38 days
期刊介绍: Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.
期刊最新文献
Real-world phenotyping and risk assessment of childhood asthma burden using national registries Predictive factors for tuberculous peripheral pulmonary lesions during radial endobronchial ultrasound Preserved ratio impaired spirometry and severity of obstructive sleep apnea: An observational cross-sectional study Is it worth screening quarry workers for TB infection in high-incidence areas? A cost-benefit analysis Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1